Security key
869367102
Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (STRO)
CUSIP: 869367102
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 56
- Total 13F value
- $1,859
- Share change
- -17,500
- SEC-reported price per share
- $33.20
- Number of holders
- 1
- Value change
- -$435,925
- Number of sells
- 1
- Shares outstanding
- 16,607,375
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
STRO full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
SUTRO BIOPHARMA, INC. SEC filings
SUTRO BIOPHARMA, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 869367102
Recent filing periods:
Ownership snapshot
Top reported holders of STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BVF INC/IL
Comparable rows
15/15
Latest evidence
24 Apr 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.6%
13D/G row: BIOTECHNOLOGY VALUE FUND L P
Showing 1-6 of 15 holder rows.
Quick read
BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 7.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership
Top 5
BIOTECHNOLOGY VALUE FUND L P
7.6%
Affinity Asset Advisors, LLC
6.5%
Samsara BioCapital, L.P.
6.4%
Point72 Asset Management, L.P.
5.7%
PERCEPTIVE ADVISORS LLC
5.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
7.6%
|
$13,306,506
1,251,788 shares
|
$0 | 10 Feb 2026 |
| Affinity Asset Advisors, LLC |
13D/G
13F
Company
|
6.5%
|
$26,642,467
1,069,519 shares
|
-$137,363,902 | 31 Mar 2026 |
| Samsara BioCapital, L.P. |
13D/G
Srinivas Akkaraju
|
6.4%
|
$26,476,886
1,062,872 shares
|
$0 | 11 Feb 2026 |
| Point72 Asset Management, L.P. |
13D/G
13F
Company
|
5.7%
|
$23,590,623
946,829 shares
|
$0 | 24 Apr 2026 |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
Company
|
5.4%
|
$22,370,431
898,025 shares
|
$0 | 14 Apr 2026 |
| Kynam Capital Management, LP |
13F
13D/G
Company
|
5.3%
from 13D/G
|
$21,735,420
872,558 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
56
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
7
Q2 2026 holders
1
Holder diff
-6
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend